CellSource Co

CellSource Co Acquisitions (Net)

The Acquisitions (Net) of CellSource Co (4880.T) as of Nov 20, 2026 is 46.82 M JPY. In the previous year, Acquisitions (Net) was -75.27 M JPY — a change of -162.20% (higher).

Acquisitions (Net)

46.82 MJPY

YoY

-162.20%

Last updated:

Acquisitions (Net) of CellSource Co is 2025 46.82 M JPY. Acquisitions (Net) of CellSource Co was 2024 -75.27 M JPY. It decreases by -162.20% higher compared to the previous year.

The CellSource Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
-65.84 M JPY
Jan 1, 2019
-54.46 M JPY
Jan 1, 2020
-25.11 M JPY
Jan 1, 2021
-194.66 M JPY
Jan 1, 2022
-70.22 M JPY
Jan 1, 2023
-265.08 M JPY
Jan 1, 2024
-75.27 M JPY
Jan 1, 2025
46.82 M JPY
The CellSource Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
46.82 MJPY-162.20%
-75.27 MJPY-71.60%
-265.08 MJPY+277.49%
-70.22 MJPY-63.93%
-194.66 MJPY+675.23%
-25.11 MJPY-53.89%
-54.46 MJPY-17.29%
-65.84 MJPY+273.21%
-17.64 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Acquisitions (Net) of CellSource Co is 46.82 M JPY in 2025.

Acquisitions (Net) of CellSource Co changed from -75.27 M JPY to 46.82 M JPY, representing a -162.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co